摘要
目的:研究汉黄芩素固体脂质纳米粒在大鼠体内的药动学及组织分布情况。方法:大鼠随机分成汉黄芩素注射液组和汉黄芩素固体脂质纳米粒组,分别于给药后不同时间采血测定汉黄芩素含量,并测定两组大鼠心、肝、脾、肺、肾中汉黄芩素含量,计算靶向效率以评价其在大鼠体内的组织分布及靶向性。结果:汉黄芩素固体脂质纳米粒在大鼠体内的药动学模型符合二室模型,主要药动学参数为:t_(1/2α)=(0.551 0±0.124 7)h,t_(1/2β)=(14.589 1±1.563 8)h,CL=(0.006 4±0.0014)ml·h·Kg^(-1),AUC_(0→8)=(125.76±9.5728)mg·h·L^(-1),其在肝脏、脾脏、心脏、肺脏及肾脏的靶向效率分别为2.003、1.789、0.634、0.707、0.259。结论:与汉黄芩素溶液相比,汉黄芩素固体脂质纳米粒能提高对肝脏、脾脏的趋向性,有利于提高其治疗作用。
Objective: To study the pharmacokinetics and distribution of wogonin solid lipid nanoparticles (SLN) in rats. Method: The plasma concentration of wogonin in rats was determined by HPLC and the pharmacokinetic parameters were calculated by soft- ware program 3P97. The targeting efficiency (To) was used to evaluate the tissue targeting of wogonin SLN. Result: The pharmacoki- netic property fitted a two - compartment model, and the main pharmacokinetic parameters of wogonin SLN were as follows: tl/2α of (0.5510+0.1247)h, t1/2β of (14.589 1+1.5638)h, CL of (0.0064+0.001 4) ml .h .kg^-1 and AUC0→8 of (125.76 + 9.572 8 ) mg ·h ·L ^- 1. Compared with that of wogonin solution, the To of live, spleen, heart, hung and kidney of wogonin SLN were 2. 003,1. 789,0. 634,0. 707 and 0. 259, respectively. Conclusion: Compared with wogonin solution, wogonin SLN show remarkable sustained-release property, and can enhance wogonin bioavailability in rats.
出处
《中国药师》
CAS
2012年第2期157-160,共4页
China Pharmacist